Regulatory
WASHINGTON (Reuters) - Eczema creams sold by Novartis AG and Astellas Pharma Inc. will come with a "black-box" warning about a possible risk of cancer from the prescription treatments, U.S. regulators said on Thursday.
A black-box warning is the strongest type used in the United States for prescription drugs.
The new warnings apply to Novartis AG's drug Elidel and Astellas Pharma's Protopic.